Sai Life Sciences Ltd
SAILIFESai Life Sciences Ltd's earnings have outrun its stock. EPS grew +102.0% in a year against a +56.0% price move.
The sharpest disagreement: annual EPS moved +102.0% against a +56.0% price move — the market has not yet caught up with the delivery.
The price is in a confirmed uptrend (55 weeks in) while the P/E sits at the 96th percentile of its own 1-year range. Underneath, the last four quarters read improving — profit +18.2% year on year, and 180% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Sai Life Sciences Ltd trades at ₹1,272, in a confirmed uptrend and 55 weeks into that stage. That is +24.6% against its own 200-day average. It sits at 100% of a 52-week range of ₹795 to ₹1,272. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 29 straight weeks.
Today the stock is in a confirmed uptrend — week 55 of stage 2, confirmed. At ₹1,272 it trades +24.6% versus its 200-day average and sits at 100% of its 52-week range (₹795–₹1,272).
Against the market, two honest reads. Cumulative: over the last 1.6 years the stock moved +81% while the NIFTY 500 moved +4% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 29 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 96th percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Sai Life Sciences Ltd trades at 73.8× P/E, at the pricey end of its own range (96th percentile). Its long-run median P/E is 64.1×, measured across 0.7 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 73.8× is at the pricey end of its own range (96th percentile), against a long-run median of 64.1× measured over 0.7 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +102.0% against a +56.0% price move — earnings outran the price, pushing the multiple DOWN its own range.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Sai Life Sciences Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 7 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +29.3% | +21.7% | +23.6% | — |
| Profit | +105.3% | +226.8% | +41.7% | — |
| EPS | +102.0% | — | — | — |
| Share price | +56.0% | — | — | — |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
61.8/100 — rank 8 of 24 in Pharma - API & CRAMS · 89% evidence confidence
Sai Life Sciences Ltd scores 61.8 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 8. Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
The four contributions add to the total exactly: 27.8 + 17 + 4.3 + 12.7 = 61.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Sai Life Sciences Ltd reported ₹602 Cr of revenue in the Mar 26 quarter, +3.8% year on year. That is the 6th straight quarter of year-on-year growth. Over 7 years it has compounded at 17.8% a year. The last full year, FY26, came in at ₹2,192 Cr. The last four reported quarters add to ₹2,191 Cr.
Sai Life Sciences Ltd reported ₹602 Cr of revenue in the Mar 26 quarter, +3.8% year on year. That is the 6th straight quarter of year-on-year growth. Over 7 years it has compounded at 17.8% a year. The last full year, FY26, came in at ₹2,192 Cr. The last four reported quarters add to ₹2,191 Cr.
FY26 revenue came in at ₹2,192 Cr (+29.3% on the year), capping 7 years at 17.8% compound. The latest quarter (Mar 26) printed ₹602 Cr, +3.8% year on year — the 6th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +35.7% growth against the decade's 17.8% — the current year is running faster than its own long-run rate.
→ Revenue grew — did margins hold as it scaled? Next: 29.0% this quarter (+2.0 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Sai Life Sciences Ltd's operating margin is 29.0% in the Mar 26 quarter, +2.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 8 fiscal years the operating margin has ranged 14.0% to 29.0%. The current quarter sits inside that band.
Sai Life Sciences Ltd's operating margin is 29.0% in the Mar 26 quarter, +2.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 8 fiscal years the operating margin has ranged 14.0% to 29.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 29.0%, +2.0 pp against the same quarter a year ago. Across 8 fiscal years the operating margin has ranged 14.0%–29.0%, and FY26's 29.0% is the top of that band — a record year.
Why the margin moved: operating margin went +2.1 pp year on year while gross margin went +2.1 pp — the gain came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
→ Margins held — did that reach the bottom line? Next: profit +18.2% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Sai Life Sciences Ltd earned ₹104 Cr of net profit in the Mar 26 quarter, +18.2% year on year. It is the 3rd consecutive quarter of growth. Full-year FY26 profit was ₹349 Cr. The 7-year compound rate is 25.0%. That is 17.3% of the quarter's revenue. The same quarter a year earlier earned ₹88.0 Cr.
Sai Life Sciences Ltd earned ₹104 Cr of net profit in the Mar 26 quarter, +18.2% year on year. It is the 3rd consecutive quarter of growth. Full-year FY26 profit was ₹349 Cr. The 7-year compound rate is 25.0%. That is 17.3% of the quarter's revenue. The same quarter a year earlier earned ₹88.0 Cr.
Mar 26 profit was ₹104 Cr, +18.2% year on year — the 3rd consecutive quarter of growth. On the full year, FY26 printed ₹349 Cr (+105.3%), and the 7-year compound rate is 25.0%.
Why profit moved: revenue contributed +3.8% and the margin +2.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +67.8% vs revenue +35.7%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
→ Profit rose — but did the cash follow? Next: 180% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 180% of Sai Life Sciences Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹509 Cr of operating cash against ₹349 Cr of profit. After ₹640 Cr of capital spending, ₹−131 Cr was left as free cash.
FY26: operating cash of ₹509 Cr against reported profit of ₹349 Cr, leaving free cash of ₹−131 Cr after ₹640 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 180% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 180%: the cash cycle tightened 20 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.
Router verdict: the bigger cash user is investment — capital spending ran 3.1× depreciation over three years, so the next section's job is to check what that build-out is buying.
→ So follow the cash to where it goes. Next: ₹1,322 Cr of building over 3 years.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Sai Life Sciences Ltd's cash conversion cycle runs −24 days in FY26, down from −4 days in FY21. Capital spending ran ₹1,322 Cr over the last 3 years. At FY26 sales of ₹2,192 Cr each day of that cycle holds about ₹6.0 Cr, so roughly ₹−144 Cr sits inside the business at any moment.
FY26: debtors at 62 days, inventory at 97 days — roughly 3.2 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of −24 days, tighter than FY21's −4.
The full loop: cash goes out to suppliers and production on day 0; stock waits 97 days to sell; customers pay about 62 days after that; and suppliers themselves are paid at 182 days — netting out to the −24-day cycle.
In money terms: at FY26 sales of ₹2,192 Cr, each day of the cycle holds about ₹6.0 Cr — so the −24-day loop keeps roughly ₹−144 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹1,322 Cr over the last 3 fiscal years against ₹425 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹270 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 20% and the ROIC − WACC spread is +1.9 pp.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Sai Life Sciences Ltd earns a ROCE of 20% in FY26. That is up from a trough of 3% in FY22. Return on invested capital clears the cost of that capital by +1.9 percentage points, so growth here adds value rather than only size. The wiring behind it is 15.9% net margin on 0.60× asset turns.
FY26 ROCE is 20%, recovered from a FY22 trough of 3% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 15.9% net margin × 0.60× asset turns × 1.46× balance-sheet leverage ≈ 13.9% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 13.9% − 12.0% = a +1.9 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.12.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Sai Life Sciences Ltd carries total debt of ₹288 Cr against shareholder equity of ₹2,484 Cr as of Mar 26, a debt-to-equity of 0.12 — effectively unlevered. On the annual view that ratio went from 0.95 in FY24 to 0.12 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹288 Cr against shareholder equity of ₹2,484 Cr — a debt-to-equity of 0.12. On the annual view, debt-to-equity went from 0.95 (FY24) to 0.12 (FY26). The returns on this page are earned, not borrowed.
→ Who owns this, and are they adding or leaving? Next: Domestic institutions added 20.8 points over 6 quarters.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions added 20.8 points of Sai Life Sciences Ltd over 6 quarters, the biggest move on the register. That takes domestic institutions to 32.7% of the company. Foreign institutions moved +7.9 points over the same window, to 19.6%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: +20.8 points over 6 quarters to 32.7%; Foreign institutions: +7.9 points over 6 quarters to 19.6%; Promoters: −0.7 points over 6 quarters to 34.5%.
Why the register moved: domestic institutions drove it (+20.8 points), alongside foreign institutions (+7.9 points) — steady accumulation by institutions reading the same numbers this page reads.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Sai Life Sciences Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Sai Life Sciences Ltd this page | 73.8× | ₹26,174 Cr | No read | |||
| Divis Laboratories Ltd | 73.4× | ₹1.9L Cr | Mixed | |||
| Laurus Labs Ltd | 79.1× | ₹86,505 Cr | Mixed | |||
| Anthem Biosciences Ltd | 73.1× | ₹43,360 Cr | No read | |||
| Gland Pharma Ltd | 37.6× | ₹39,257 Cr | Improving | |||
| Acutaas Chemicals Ltd | 75.2× | ₹26,785 Cr | Improving | |||
| Acutaas Chemicals Ltd | 69.1× | ₹26,686 Cr | Mixed | |||
| Piramal Pharma Ltd | — | ₹24,133 Cr | No read | |||
| Neuland Laboratories Ltd | 65.9× | ₹23,794 Cr | Turning around | |||
| Granules India Ltd | 31.8× | ₹20,655 Cr | Consistent | |||
| OneSource Specialty Pharma Ltd | — | ₹18,961 Cr | No read | |||
| Syngene International Ltd | 44.9× | ₹16,708 Cr | Turning around | |||
| Syngene International Ltd | 44.1× | ₹16,415 Cr | Turning around | |||
| Cohance Lifesciences Ltd | 80.9× | ₹15,957 Cr | Deteriorating | |||
| Jubilant Pharmova Ltd | 35.2× | ₹15,378 Cr | No read | |||
| Concord Biotech Ltd | 54.8× | ₹13,061 Cr | Deteriorating | |||
| Shilpa Medicare Ltd | 50.8× | ₹11,856 Cr | No read | |||
| Blue Jet Healthcare Ltd | 43.3× | ₹10,730 Cr | Deteriorating | |||
| Supriya Lifescience Ltd | 32.3× | ₹6,765 Cr | Consistent | |||
| IOL Chemicals & Pharmaceuticals Ltd | 30.0× | ₹4,380 Cr | Improving | |||
| SMS Pharmaceuticals Ltd | 35.0× | ₹3,569 Cr | Mixed | |||
| Morepen Laboratories Ltd | 39.6× | ₹2,948 Cr | Mixed | |||
| Dishman Carbogen Amcis Ltd | 29.0× | ₹2,878 Cr | No read | |||
| Hikal Ltd | 73.8× | ₹2,681 Cr | Deteriorating | |||
| Solara Active Pharma Sciences Ltd | 551.0× | ₹2,351 Cr | No read | |||
| Windlas Biotech Ltd | 26.6× | ₹1,770 Cr | Mixed |
Frequently asked questions
What is Sai Life Sciences Ltd's share price today?
Sai Life Sciences Ltd trades at ₹1,272, +56.0% over the past year. The company is valued at ₹26,174 Cr. The stock sits at 100% of its 52-week range of ₹795–₹1,272, +24.6% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 55 weeks in. — as of 24 July 2026.
What were Sai Life Sciences Ltd's latest quarterly results?
Sai Life Sciences Ltd reported revenue of ₹602 Cr and net profit of ₹104 Cr for the Mar 26 quarter. Revenue rose 3.8% and profit rose 18.2% year on year. Earnings per share were ₹4.92. The operating margin was 29.0%, 2.0 pp higher than a year earlier. — as of 24 July 2026.
What is Sai Life Sciences Ltd's revenue?
Sai Life Sciences Ltd reported revenue of ₹602 Cr in the Mar 26 quarter, +3.8% year on year. For the full FY26 fiscal year, revenue was ₹2,192 Cr (+29.3%). Over the last 7 years revenue compounded at 17.8% a year. — as of 24 July 2026.
What is Sai Life Sciences Ltd's profit?
Sai Life Sciences Ltd earned ₹104 Cr of net profit in the Mar 26 quarter, +18.2% year on year — the 3rd straight quarter of growth. Full-year FY26 profit was ₹349 Cr. The operating margin ran 29.0% in the latest quarter. — as of 24 July 2026.
What is Sai Life Sciences Ltd's market cap?
Sai Life Sciences Ltd's market capitalisation is ₹26,174 Cr at a share price of ₹1,272. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Sai Life Sciences Ltd's P/E ratio?
Sai Life Sciences Ltd trades at a P/E of 73.8×, at the 96th percentile of its own 1-year range, against a long-run median of 64.1×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does Sai Life Sciences Ltd pay a dividend?
Not in its latest year — Sai Life Sciences Ltd's dividend payout was 0% of profit in FY26. It did record a payout in 2 of its last 8 reported fiscal years, so there is a history but no current dividend. — as of 24 July 2026.
Is Sai Life Sciences Ltd overvalued?
On its own history, Sai Life Sciences Ltd looks expensive against its own history: its P/E of 73.8× sits at the 96th percentile of its 1-year range (long-run median 64.1×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 24 July 2026.
Is Sai Life Sciences Ltd growing?
Yes — Sai Life Sciences Ltd is growing: latest-quarter revenue +3.8% year on year, profit +18.2%, and the margin +2.0 pp at 29.0%. The 7-year compound rates are 17.8% (revenue) and 25.0% (profit). The earnings engine currently reads: improving — as of 24 July 2026.
How is Sai Life Sciences Ltd performing?
Sai Life Sciences Ltd is in a confirmed uptrend, 55 weeks in. Its latest quarter's revenue rose 3.8% and profit rose 18.2% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 29 weeks. This describes what the data did, not a rating. — as of 24 July 2026.
Is Sai Life Sciences Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 55 of stage 2), trading +24.6% versus its 200-day average and at 100% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Sai Life Sciences Ltd beating the market?
On recent form, yes — Sai Life Sciences Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 29 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 1.6 years the stock moved +81% against the NIFTY 500's +4% — ahead of the index over the full window. — as of 24 July 2026.
Will Sai Life Sciences Ltd's share price go up?
This page publishes no price forecast for Sai Life Sciences Ltd. What it measures instead: the share price is ₹1,272, the price is in a confirmed uptrend 55 weeks in. Its P/E of 73.8× sits at the 96th percentile of its own 1-year range. — as of 24 July 2026.
Who owns Sai Life Sciences Ltd?
Promoters hold 34.5% of Sai Life Sciences Ltd, foreign institutions 19.6%, domestic institutions 32.7% and the public 13.1% (latest quarter). The biggest move on the register over the last two years: Domestic institutions added 20.8 points over 6 quarters. — as of 24 July 2026.
Does Sai Life Sciences Ltd have too much debt?
No — Sai Life Sciences Ltd's debt-to-equity is 0.12, and operating profit covers the interest bill 16×. FY26 borrowings were ₹288 Cr against equity of ₹2,484 Cr. The returns on this page are earned, not borrowed — as of 24 July 2026.
What is Sai Life Sciences Ltd's capex?
Sai Life Sciences Ltd spent ₹1,322 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹640 Cr, with ₹270 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Sai Life Sciences Ltd's cash flow?
Sai Life Sciences Ltd generated ₹509 Cr of operating cash flow in FY26 and ₹−131 Cr of free cash flow after ₹640 Cr of capital spending. Reported profit that year was ₹349 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Sai Life Sciences Ltd's profit real cash?
Yes — over the last 3 fiscal years, 180% of Sai Life Sciences Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹509 Cr against reported profit of ₹349 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 24 July 2026.
Where is Sai Life Sciences Ltd in its business cycle?
Sai Life Sciences Ltd's FY26 operating margin was 29.0%, against a 8-year band of 14.0%–29.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 29.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Sai Life Sciences Ltd story?
The sharpest disagreement: annual EPS moved +102.0% against a +56.0% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Sai Life Sciences Ltd a stock worth studying right now?
This is not investment advice. The machine read: Sai Life Sciences Ltd's earnings have outrun its stock. EPS grew +102.0% in a year against a +56.0% price move. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.